Actavis begins shipping Morphine Sulfate Extended-Release Capsules

NewsGuard 100/100 Score
Nov 11 2011

Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Morphine Sulfate Extended-Release Capsules, USP CII, an authorized generic of KADIAN®.

Actavis has been manufacturing KADIAN® for 15 years and has in-depth expertise in the development and manufacturing of complex controlled-release pharmaceuticals.  

KADIAN® US sales have grown 50% in the last 5 years to approximately $275 million for the 12 months ending September 30, 2011, according to IMS Health.  

Source:

Actavis Inc.

Posted in: Pharmaceutical News

Tags: , ,

Comments (0)

Suggested Reading

Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles
Common HIV drugs linked to reduced Alzheimer's disease risk
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Researchers receive NIH grant to help develop gene therapy for HIV
Recycled food waste may be contaminated with pharmaceutical residues, research reveals
MD Anderson and CureVac collaborate on mRNA-based cancer vaccines
Researchers develop new way to make vegan food more appetizing
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Lancet Commission predicts sharp increase in global prostate cancer cases